We have written about the promise of gene therapy to correct genetic disease many times. An exciting development happened ...

In a world first, a bespoke gene-editing therapy benefited one child. Now researchers plan to launch a clinical trial of the approach ...

Some of the most expensive drugs currently in use are gene therapies to treat specific diseases, and their high cost limits ...

In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...

Gene therapy has the potential to dramatically benefit patients with genetic blood disorders, but a small study on participants in a clinical trial for sickle cell disease suggests that a key process ...

The FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the ...

With the FDA expecting to approve 10–20 Cell and Gene Therapies (CGTs) annually by 2025, it is evident that the field will continue to hold immense commercial and medical opportunities. To harness ...

Last May, people were thrilled to learn that a 7-month-old baby who became the first in the world to receive a personalized ...

The Product Shortage PLUS Endorsement was developed in consultation with Cell One Partners Inc., a world leader in helping cell and gene therapy companies advance and achieve growth objectives toward ...

Oncologists' experience with CGT has increased, with more patients treated and earlier lines of therapy being utilized.

Lilly’s upfront offer for Adverum, the developer of a gene therapy for age-related macular degeneration, is less than the ...

The cell and gene therapy quality control market size is calculated at USD 2.87 billion in 2025 and is expected to reach ...